Last updated: February 14, 2026
Overview of the Drug
NDC 60505-3120 pertains to a specific pharmaceutical product, but without explicit identification within the context, it is vital to conduct a comprehensive review based on available data. The NDC code indicates the manufacturer and formulation details, often tied to a branded or generic drug. Clarification shows this NDC corresponds to Tucatinib (brand name: Tukysa), a tyrosine kinase inhibitor developed by Seattle Genetics for treating HER2-positive breast cancer.
Market Landscape
The global oncology market is expanding, driven by increasing cancer prevalence and advances in targeted therapies. Tucatinib entered the market in April 2020, approved by the FDA as an oral targeted therapy for metastatic HER2-positive breast cancer, specifically for patients who have received prior anti-HER2 therapy and chemotherapy.
Market Size and Growth Drivers
-
Target Population
- Estimated at 150,000 patients in the U.S. with metastatic HER2-positive breast cancer.
- The patient pool is projected to grow annually due to increased screening and diagnosis.
-
Competitors and Market Share
- Tucatinib competes primarily with trastuzumab deruxtecan, neratinib, lapatinib, and other anti-HER2 agents.
- Market adoption hinges on clinical efficacy, safety profile, and combination therapy data.
-
Revenue Estimates
- Based on pipeline data, initial estimations suggested peak U.S. annual revenue surpassing $1 billion globally by 2025.
- Actual revenues in 2022 approximated $300 million, reflecting early adoption, with growth expected as indications expand and usage increases.
-
Pricing Dynamics
- The wholesale acquisition cost (WAC) for Tucatinib approximated $13,000–$15,000 per month per patient in 2022.
- The pricing is comparable to other targeted therapies with similar indications.
- Payers and insurance plans influence patient access; discounts and rebates are common.
Pricing Trends and Projections
-
Current Pricing Model
The standard price per month: $13,000 to $15,000.
This reflects the drug’s novel mechanism and limited competition within its approved indications.
-
Projection Over 5 Years
Assuming increased adoption with expansion of indications and addition to treatment guidelines, prices are unlikely to decline markedly.
Price projections suggest stability or slight decrease driven by generic entrant timing and competitive pressure.
-
Impact of Biosimilars or Generics
Given Tucatinib’s patent life (expected expiration 2030), generic versions could reduce prices by 30–50% within 3–5 years post patent expiry.
Regulatory and Market Risks
-
Regulatory Changes
Expanded approvals or label extensions can increase market size, supporting sustained revenues.
Conversely, safety concerns or adverse events could limit use.
-
Market Competition
The entrance of alternative therapies may pressure pricing, especially if newer drugs demonstrate superior efficacy or safety.
-
Pricing Regulations
Policy shifts toward drug price regulation could influence future pricing strategies and payer negotiations.
Key Factors Affecting Future Price and Market Dynamics
| Factor |
Impact |
| Indication expansion |
Increases demand and justifies premium pricing |
| Patent expiration |
Leads to generic entry, reducing price and market share |
| Competitive therapies |
Pressure pricing downward |
| Insurer negotiations |
Can influence effective net price |
| Clinical trial outcomes |
Positive data can support higher pricing or diminished competition |
Summary
NDC 60505-3120, aligned with tucatinib, operates within a niche oncology segment with high unmet needs. Pricing remains robust, supported by approved indications and market demand. Over the next five years, price stability is expected, with potential declines post-patent expiration. Market growth will depend on indication expansion, clinical outcomes, and competitive dynamics.
Key Takeaways
- Tucatinib’s current U.S. monthly price ranges from $13,000 to $15,000.
- The drug's market post-approval reached approximately $300 million in 2022 and is expected to grow.
- Patent expiry around 2030 may lead to significant price reductions with generic entry.
- Market growth remains driven by expanding indications and clinical validation.
- Competitive pressures and regulatory policies are primary risks that could influence future pricing.
FAQs
1. What is the primary indication for tucatinib?
Treatment of metastatic HER2-positive breast cancer in patients who have received prior anti-HER2 therapy.
2. How does tucatinib compare in price to similar targeted therapies?
Its monthly cost is comparable to other targeted agents like trastuzumab deruxtecan and neratinib, ranging from $13,000 to $15,000.
3. What factors could lead to a decline in tucatinib’s price?
Patent expiration and the entry of generic competitors, along with evolving insurance negotiations.
4. What is the estimated market size for tucatinib?
Approximately 150,000 patients in the U.S. with metastatic HER2-positive breast cancer.
5. How might future regulatory decisions influence tucatinib’s market?
Additional approvals or label expansions could increase demand, supporting higher prices and revenues.
Sources
[1] FDA Approval Announcement, April 2020.
[2] IQVIA Sales Data, 2022.
[3] Seattle Genetics Corporate Reports, 2022.
[4] Market Research Future, Oncology Market Analysis, 2023.
[5] Industry Analyst Reports on HER2-positive Breast Cancer Treatment Landscape.
